PitchSend

Investor Presentaiton

With the addition of Kerecis, Coloplast aims to reach many more. patients in need of wound treatment, accelerating growth to 8-10% kerecis Mission: To become the world leader in tissue regeneration by sustainably harnessing nature's own remedies Mission: Making life easier for people with intimate healthcare needs 46 Long-term financial guidance کرا 8-10% Coloplast organic growth p.a. 100 more than 30% EBIT margin beyond 2024/251 1 For the remaining Strive25 strategic period running until end 2024/25, the EBIT margin is now expected to remain below 30%, and assumes dilution of around 100 basis points p.a. from Kerecis (including PPA amortisation) Coloplast

View entire presentation